Minor changes to the WP3 webpage text

Added one missing reference and corrected a spelling mistake.

Author: danielwitte

wp3.qmd

@@ -21,10 +21,10 @@ The current vision for precision prevention integrates data from genetic, biolog
 WP3 establishes such a cohort across Steno Centers with long-term academic and strategic visions. The strategic vision is to establish the facilities, expertise and capacity across all Steno Centers to carry out multi-center clinical studies with a standardised protocol and management/data infrastructure. We also want to prepare the centers for the standardised application of deep phenotyping close to clinical practice by applying a high degree of standardisation, openness and reproducibility ([WP1](https://steno-aarhus.github.io/dp-next/wp1/)).
 
 ### Academic Objectives:
-Academically, we describe a core protocol, which will be carried out within the DP-Next budget and timeframe, and an extended protocol, which describes our ambitions for deeper phenotyping and longer follow-up. Funding for the extended protocol will be sought separately on a project basis and will build on the capacity established in the core protocol. Connection and coordination will be sought with new Danish phenotyping initiatives currently underway or in the planning process (e.g. PRECiSE).
+Academically, we describe a core protocol, which will be carried out within the DP-Next budget and timeframe, and an extended protocol, which describes our ambitions for deeper phenotyping and longer follow-up. Funding for the extended protocol will be sought separately on a project basis and will build on the capacity established in the core protocol. Connection and coordination will be sought with new Danish phenotyping initiatives currently underway or in the planning process (e.g. PRECISE).
 
 ### Who will be included:
-In the core protocol we will identify a cohort of 1000 individuals aged 40 to 55 years who have recently (within the past 12 months) had a routine HbA1c measurement in the pre-diabetic range (42-47 mmol/mol) and are not using any glucose lowering medication. This age range was chosen to maximise life-long impact on diabetes risk. Sample size calculations use our recent analysis of HbA1c defined (pre)diabetes in Denmark1, showing that 25 to 40% of Danish residents aged 40-55 had at least 1 HbA1c measurement in 2018. In our target age range pre-diabetes incidence was 9/1000 person years, and the subsequent incidence of diabetes was 7/1000, and hence an expected cumulative T2D incidence of 22% in a median of 3.5 years of follow-up. Logistic regression based power calculations show that a cohort of 1050 individuals gives us 0.9 power at a 0.05 significance level to detect an odds ratio of at least 1.28 per standard deviation in a continuous exposure variable.
+In the core protocol we will identify a cohort of 1000 individuals aged 40 to 55 years who have recently (within the past 12 months) had a routine HbA1c measurement in the pre-diabetic range (42-47 mmol/mol) and are not using any glucose lowering medication. This age range was chosen to maximise life-long impact on diabetes risk. Sample size calculations use our recent analysis of HbA1c defined (pre)diabetes in Denmark[@Nicolaisen2023], showing that 25 to 40% of Danish residents aged 40-55 had at least 1 HbA1c measurement in 2018. In our target age range pre-diabetes incidence was 9/1000 person years, and the subsequent incidence of diabetes was 7/1000, and hence an expected cumulative T2D incidence of 22% in a median of 3.5 years of follow-up. Logistic regression based power calculations show that a cohort of 1050 individuals gives us 0.9 power at a 0.05 significance level to detect an odds ratio of at least 1.28 per standard deviation in a continuous exposure variable.
 
 ### Recruitment:
 Participants will be recruited in Odense (350), Aarhus (350), Aalborg (150), Greenland (50) and the Faroe Islands (50). We intend to include 100 individuals of Greenlandic ancestry, 50 living in Denmark and 50 living in Greenland. Participants will be recruited based on data from routine HbA1c checks, accessed through the LABKA registers. Consequently the clinical decisions prompting a HbA1c measurement will form part of the selection process, reflecting current clinical practice.